| pubmed-article:15801034 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15801034 | lifeskim:mentions | umls-concept:C0024143 | lld:lifeskim |
| pubmed-article:15801034 | lifeskim:mentions | umls-concept:C0151436 | lld:lifeskim |
| pubmed-article:15801034 | lifeskim:mentions | umls-concept:C0334094 | lld:lifeskim |
| pubmed-article:15801034 | lifeskim:mentions | umls-concept:C0717758 | lld:lifeskim |
| pubmed-article:15801034 | lifeskim:mentions | umls-concept:C2709058 | lld:lifeskim |
| pubmed-article:15801034 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15801034 | pubmed:dateCreated | 2005-3-31 | lld:pubmed |
| pubmed-article:15801034 | pubmed:abstractText | Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA. | lld:pubmed |
| pubmed-article:15801034 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15801034 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801034 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15801034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801034 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15801034 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15801034 | pubmed:issn | 0315-162X | lld:pubmed |
| pubmed-article:15801034 | pubmed:author | pubmed-author:BarisoniLaura... | lld:pubmed |
| pubmed-article:15801034 | pubmed:author | pubmed-author:MorAdamA | lld:pubmed |
| pubmed-article:15801034 | pubmed:author | pubmed-author:BinghamClifto... | lld:pubmed |
| pubmed-article:15801034 | pubmed:author | pubmed-author:LydonEileenE | lld:pubmed |
| pubmed-article:15801034 | pubmed:author | pubmed-author:BelmontH... | lld:pubmed |
| pubmed-article:15801034 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15801034 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:15801034 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15801034 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15801034 | pubmed:pagination | 740-3 | lld:pubmed |
| pubmed-article:15801034 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:meshHeading | pubmed-meshheading:15801034... | lld:pubmed |
| pubmed-article:15801034 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15801034 | pubmed:articleTitle | Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. | lld:pubmed |
| pubmed-article:15801034 | pubmed:affiliation | Division of Rheumatology, Department of Medicine, New York University School of Medicine/Hospital for Joint Diseases, New York, New York, USA. mora01@med.nyu.edu | lld:pubmed |
| pubmed-article:15801034 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15801034 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801034 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801034 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801034 | lld:pubmed |
